Dr Carolyn Bampton

Dr Carolyn Bampton is an accomplished medical oncologist specialising in the field of oncology. She serves as a primary practitioner in the suburb of Kurralta Park, located in Adelaide, South Australia, Australia. With a reputable background and extensive experience, Dr Bampton is affiliated with prestigious hospitals.

After completing her medical education at the University of Adelaide, Dr Carolyn Bampton obtained her MBBS degree, reflecting her exceptional qualifications. She later pursued specialised training in oncology at the renowned Royal Adelaide Hospital to further refine her skills and expertise in this challenging medical field. Furthermore, she ventured into palliative medicine at Sydney's Concord Hospital from 1997-1998, augmenting her comprehensive knowledge and integrative approach to patient care.

Dr Bampton's dedication and proficiency led her to join the esteemed team at Icon Cancer Centre Adelaide, where she actively contributes to patient treatments and provides unparalleled care. In addition to her role at Icon Cancer Centre Adelaide, Dr Carolyn Bampton has also held the esteemed position of visiting medical oncologist at the Modbury Public Hospital for over 12 years.

Driven by a commitment to medical education, research, and innovation, Dr Carolyn Bampton actively participates in clinical trials and contributes to medical advancements. As a clinical advisor for the Adelaide Community Health Care Alliance hospitals Medical Advisory Committee, she shares her valuable insights and expertise. Dr Bampton also holds the position of senior clinical lecturer at Adelaide University, further supporting her dedication to medical education and developing the next generation of medical professionals.

Dr Carolyn Bampton's clinical experience covers a wide spectrum of solid tumor malignancies. With a special interest in gastrointestinal cancer, brain and spinal (CNS) cancer, breast cancer, lung cancer, and prostate cancer, she strives to provide personalized and effective treatment plans for her patients. Throughout her career, she has also participated as a principal investigator and co-principal investigator in several clinical trials focusing on gastrointestinal cancers.

Furthermore, Dr Bampton's contributions to medical literature are commendable. She is recognized for her involvement in groundbreaking research and studies. Notably, she has been credited for her work in publications such as the Gut journal ("Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study") and The Lancet ("Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial").

With an unwavering dedication to patient care, medical education, and clinical research, Dr Carolyn Bampton continues to make a significant impact in the field of oncology. Her expertise, compassionate approach, and commitment to advancements in cancer treatment have earned her the admiration of both patients and colleagues alike.